PortalPublikationenEffectiveness of Adjuvant Chemotherapy After Radical Cystect...

Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder

Standard

Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder : A Propensity Score-Weighted Competing Risks Analysis. / Vetterlein, Malte W; Seisen, Thomas; May, Matthias; Nuhn, Philipp; Gierth, Michael; Mayr, Roman; Fritsche, Hans-Martin; Burger, Maximilian; Novotny, Vladimir; Froehner, Michael; Wirth, Manfred P; Protzel, Chris; Hakenberg, Oliver W; Roghmann, Florian; Palisaar, Rein-Jüri; Noldus, Joachim; Pycha, Armin; Bastian, Patrick J; Trinh, Quoc-Dien; Xylinas, Evanguelos; Shariat, Shahrokh F; Rink, Michael; Chun, Felix K-H; Dahlem, Roland; Fisch, Margit; Aziz, Atiqullah; PROMETRICS 2011 study group.

in: EUR UROL FOCUS, 18.07.2016.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Vetterlein, MW, Seisen, T, May, M, Nuhn, P, Gierth, M, Mayr, R, Fritsche, H-M, Burger, M, Novotny, V, Froehner, M, Wirth, MP, Protzel, C, Hakenberg, OW, Roghmann, F, Palisaar, R-J, Noldus, J, Pycha, A, Bastian, PJ, Trinh, Q-D, Xylinas, E, Shariat, SF, Rink, M, Chun, FK-H, Dahlem, R, Fisch, M, Aziz, A & PROMETRICS 2011 study group 2016, 'Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis', EUR UROL FOCUS. https://doi.org/10.1016/j.euf.2016.07.001

APA

Vetterlein, M. W., Seisen, T., May, M., Nuhn, P., Gierth, M., Mayr, R., Fritsche, H-M., Burger, M., Novotny, V., Froehner, M., Wirth, M. P., Protzel, C., Hakenberg, O. W., Roghmann, F., Palisaar, R-J., Noldus, J., Pycha, A., Bastian, P. J., Trinh, Q-D., ... PROMETRICS 2011 study group (2016). Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. EUR UROL FOCUS. https://doi.org/10.1016/j.euf.2016.07.001

Vancouver

Vetterlein MW, Seisen T, May M, Nuhn P, Gierth M, Mayr R et al. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. EUR UROL FOCUS. 2016 Jul 18. https://doi.org/10.1016/j.euf.2016.07.001

Bibtex

@article{c97e100460c1457e9f2496b32b3fa112,
title = "Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis",
abstract = "BACKGROUND: The benefit of adjuvant chemotherapy (AC) for muscle-invasive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC) is controversial.OBJECTIVE: To assess the effectiveness of AC after RC for muscle-invasive UCB in contemporary European routine practice.DESIGN, SETTING, AND PARTICIPANTS: By using a prospectively collected European multicenter database, we compared survival outcomes between patients who received AC versus observation after RC for locally advanced (pT3/T4) and/or pelvic lymph node-positive (pN+) muscle-invasive UCB in 2011.INTERVENTION: AC versus observation after RC.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Inverse probability of treatment weighting (IPTW)-adjusted Cox regression and competing risks analyses were performed to compare overall survival (OS) as well as cancer-specific and other-cause mortality between patients who received AC versus observation.RESULTS AND LIMITATIONS: Overall, 224 patients who received AC (n = 84) versus observation (n = 140) were included. The rate of 3-yr OS in patients who received AC versus observation was 62.1% versus 40.9%, respectively (p = 0.014). In IPTW-adjusted Cox regression analysis, AC versus observation was associated with an OS benefit (hazard ratio: 0.47; 95% confidence interval [CI]: 0.25-0.86; p = 0.014). In IPTW-adjusted competing risks analysis, AC versus observation was associated with a decreased risk of cancer-specific mortality (subhazard ratio: 0.51; 95% CI: 0.26-0.98; p = 0.044) without any increased risk of other-cause mortality (subhazard ratio: 0.48; 95% CI: 0.14-1.60; p = 0.233). Limitations include the relatively small sample size as well as the potential presence of unmeasured confounders related to the observational study design.CONCLUSIONS: We found that AC versus observation was associated with a survival benefit after RC in patients with pT3/T4 and/or pN+ UCB. These results should encourage physicians to deliver AC and researchers to pursue prospective or large observational investigations.PATIENT SUMMARY: Overall survival and cancer-specific survival benefit was found in patients who received adjuvant chemotherapy relative to observation after radical cystectomy for locally advanced and/or pelvic lymph node-positive bladder cancer.",
keywords = "Journal Article",
author = "Vetterlein, {Malte W} and Thomas Seisen and Matthias May and Philipp Nuhn and Michael Gierth and Roman Mayr and Hans-Martin Fritsche and Maximilian Burger and Vladimir Novotny and Michael Froehner and Wirth, {Manfred P} and Chris Protzel and Hakenberg, {Oliver W} and Florian Roghmann and Rein-J{\"u}ri Palisaar and Joachim Noldus and Armin Pycha and Bastian, {Patrick J} and Quoc-Dien Trinh and Evanguelos Xylinas and Shariat, {Shahrokh F} and Michael Rink and Chun, {Felix K-H} and Roland Dahlem and Margit Fisch and Atiqullah Aziz and {PROMETRICS 2011 study group}",
note = "Copyright {\textcopyright} 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2016",
month = jul,
day = "18",
doi = "10.1016/j.euf.2016.07.001",
language = "English",
journal = "EUR UROL FOCUS",
issn = "2405-4569",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder

T2 - A Propensity Score-Weighted Competing Risks Analysis

AU - Vetterlein, Malte W

AU - Seisen, Thomas

AU - May, Matthias

AU - Nuhn, Philipp

AU - Gierth, Michael

AU - Mayr, Roman

AU - Fritsche, Hans-Martin

AU - Burger, Maximilian

AU - Novotny, Vladimir

AU - Froehner, Michael

AU - Wirth, Manfred P

AU - Protzel, Chris

AU - Hakenberg, Oliver W

AU - Roghmann, Florian

AU - Palisaar, Rein-Jüri

AU - Noldus, Joachim

AU - Pycha, Armin

AU - Bastian, Patrick J

AU - Trinh, Quoc-Dien

AU - Xylinas, Evanguelos

AU - Shariat, Shahrokh F

AU - Rink, Michael

AU - Chun, Felix K-H

AU - Dahlem, Roland

AU - Fisch, Margit

AU - Aziz, Atiqullah

AU - PROMETRICS 2011 study group

N1 - Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2016/7/18

Y1 - 2016/7/18

N2 - BACKGROUND: The benefit of adjuvant chemotherapy (AC) for muscle-invasive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC) is controversial.OBJECTIVE: To assess the effectiveness of AC after RC for muscle-invasive UCB in contemporary European routine practice.DESIGN, SETTING, AND PARTICIPANTS: By using a prospectively collected European multicenter database, we compared survival outcomes between patients who received AC versus observation after RC for locally advanced (pT3/T4) and/or pelvic lymph node-positive (pN+) muscle-invasive UCB in 2011.INTERVENTION: AC versus observation after RC.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Inverse probability of treatment weighting (IPTW)-adjusted Cox regression and competing risks analyses were performed to compare overall survival (OS) as well as cancer-specific and other-cause mortality between patients who received AC versus observation.RESULTS AND LIMITATIONS: Overall, 224 patients who received AC (n = 84) versus observation (n = 140) were included. The rate of 3-yr OS in patients who received AC versus observation was 62.1% versus 40.9%, respectively (p = 0.014). In IPTW-adjusted Cox regression analysis, AC versus observation was associated with an OS benefit (hazard ratio: 0.47; 95% confidence interval [CI]: 0.25-0.86; p = 0.014). In IPTW-adjusted competing risks analysis, AC versus observation was associated with a decreased risk of cancer-specific mortality (subhazard ratio: 0.51; 95% CI: 0.26-0.98; p = 0.044) without any increased risk of other-cause mortality (subhazard ratio: 0.48; 95% CI: 0.14-1.60; p = 0.233). Limitations include the relatively small sample size as well as the potential presence of unmeasured confounders related to the observational study design.CONCLUSIONS: We found that AC versus observation was associated with a survival benefit after RC in patients with pT3/T4 and/or pN+ UCB. These results should encourage physicians to deliver AC and researchers to pursue prospective or large observational investigations.PATIENT SUMMARY: Overall survival and cancer-specific survival benefit was found in patients who received adjuvant chemotherapy relative to observation after radical cystectomy for locally advanced and/or pelvic lymph node-positive bladder cancer.

AB - BACKGROUND: The benefit of adjuvant chemotherapy (AC) for muscle-invasive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC) is controversial.OBJECTIVE: To assess the effectiveness of AC after RC for muscle-invasive UCB in contemporary European routine practice.DESIGN, SETTING, AND PARTICIPANTS: By using a prospectively collected European multicenter database, we compared survival outcomes between patients who received AC versus observation after RC for locally advanced (pT3/T4) and/or pelvic lymph node-positive (pN+) muscle-invasive UCB in 2011.INTERVENTION: AC versus observation after RC.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Inverse probability of treatment weighting (IPTW)-adjusted Cox regression and competing risks analyses were performed to compare overall survival (OS) as well as cancer-specific and other-cause mortality between patients who received AC versus observation.RESULTS AND LIMITATIONS: Overall, 224 patients who received AC (n = 84) versus observation (n = 140) were included. The rate of 3-yr OS in patients who received AC versus observation was 62.1% versus 40.9%, respectively (p = 0.014). In IPTW-adjusted Cox regression analysis, AC versus observation was associated with an OS benefit (hazard ratio: 0.47; 95% confidence interval [CI]: 0.25-0.86; p = 0.014). In IPTW-adjusted competing risks analysis, AC versus observation was associated with a decreased risk of cancer-specific mortality (subhazard ratio: 0.51; 95% CI: 0.26-0.98; p = 0.044) without any increased risk of other-cause mortality (subhazard ratio: 0.48; 95% CI: 0.14-1.60; p = 0.233). Limitations include the relatively small sample size as well as the potential presence of unmeasured confounders related to the observational study design.CONCLUSIONS: We found that AC versus observation was associated with a survival benefit after RC in patients with pT3/T4 and/or pN+ UCB. These results should encourage physicians to deliver AC and researchers to pursue prospective or large observational investigations.PATIENT SUMMARY: Overall survival and cancer-specific survival benefit was found in patients who received adjuvant chemotherapy relative to observation after radical cystectomy for locally advanced and/or pelvic lymph node-positive bladder cancer.

KW - Journal Article

U2 - 10.1016/j.euf.2016.07.001

DO - 10.1016/j.euf.2016.07.001

M3 - SCORING: Journal article

C2 - 28753775

JO - EUR UROL FOCUS

JF - EUR UROL FOCUS

SN - 2405-4569

ER -